Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
02/22/2011 | US7892773 Expression vector comprising nucleotide sequences coding homeobox transcriptional regulator gene for identifying modulators for treatment and prevention of cell proliferative disorders of urogenital system |
02/22/2011 | US7892569 agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides; to decrease an immune response; antagonist of ADAM-10 is GW280264X, G1254023X or GM6001 |
02/22/2011 | US7892554 Using immunoglobulin fusion to deliver effector cells; tissue targeted therapy; antitumor agents |
02/22/2011 | US7892549 Treatment with anti-ErbB2 antibodies |
02/22/2011 | US7892531 Human serum albumin(HSA); solubilized in low-ionic-strength buffer with specified ph; glycine, aspartic acid, sodium succinate, trehalose; binds with receptors |
02/22/2011 | CA2485909C Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
02/22/2011 | CA2476296C Amino-derivatives as inhibitors of histone deacetylase |
02/22/2011 | CA2441566C Blood cell production via activation of the hemoglobin scavenger receptor |
02/22/2011 | CA2435877C Prevention of diabetes by administration of gnrh antagonists |
02/22/2011 | CA2435503C Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
02/22/2011 | CA2423833C Viruses targeted to hypoxic cells and tissues |
02/22/2011 | CA2410193C Neuronal serine-threonine protein kinase |
02/22/2011 | CA2359109C Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
02/22/2011 | CA2185998C The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure |
02/17/2011 | WO2011019065A1 Tumor angiogenesis inhibitor |
02/17/2011 | WO2011019023A1 Agent for ameliorating blood-brain barrier disorders |
02/17/2011 | WO2011018488A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
02/17/2011 | WO2011018487A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
02/17/2011 | WO2011018482A1 Stabilised particles comprising 5-methyl-(6s)-tetrahydrofolate |
02/17/2011 | US20110040240 Methods for treating rhinitis and conjunctivitis |
02/17/2011 | US20110040161 Device for generating a detectable signal based upon concentration of at least one substance |
02/17/2011 | US20110039899 Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH |
02/17/2011 | US20110039863 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
02/17/2011 | US20110039759 Use of Secretin-Receptor Ligands in Treatment of Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) |
02/17/2011 | US20110039279 Methods and compositions for diagnosing breast cancer |
02/17/2011 | US20110038953 Strontium compound for treatment of sub-dermal soft tissue pain |
02/17/2011 | US20110038918 Composition For Transdermal Delivery of Fentanyl |
02/17/2011 | US20110038868 Il-17 homologous polypeptides and therapeutic uses thereof |
02/17/2011 | DE102009035211A1 Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung Coprecipitates comprising a phosphodiesterase-5 inhibitor (PDE-5) inhibitor and a pharmaceutically acceptable carrier, their preparation and use |
02/17/2011 | CA2770678A1 Methods of monitoring endoplasmic reticulum (er) stress response |
02/17/2011 | CA2770441A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
02/17/2011 | CA2769803A1 Stabilised particles comprising 5-methyl-(6s)-tetrahydrofolate |
02/16/2011 | EP2284264A1 Induction of exon skipping in eukaryotic cells |
02/16/2011 | EP2284190A2 Transfer factor from birds eggs |
02/16/2011 | EP2284189A2 Nucleic acid molecules encoding fibroblast growth factor-like (FGF-like) polypeptides |
02/16/2011 | EP2283872A2 Non-covalent bioconjugates useful for diagnosis and therapy |
02/16/2011 | EP2283869A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer |
02/16/2011 | EP2283868A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer |
02/16/2011 | EP2283865A1 Method of increasing testosterone and related steroid concentrations in women |
02/16/2011 | EP2283862A1 Antitumor agent |
02/16/2011 | EP2283845A1 Sustained release drug delivery system containing codrugs |
02/16/2011 | EP2283842A1 Tamper-resitant oral opioid agonist formulations |
02/16/2011 | EP2283841A1 Selective serotonin receptor inverse agonists as therapeutics for disease |
02/16/2011 | EP2283838A2 Docosahexaenoic acid for treating subclinical inflammation |
02/16/2011 | EP2283837A2 Docosahexaenoic acid for treating subclinical inflammation |
02/16/2011 | EP2283835A2 Method and preparation for treating metabolic stress |
02/16/2011 | EP2283822A2 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
02/16/2011 | EP2282779A1 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response |
02/16/2011 | EP2282778A2 New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
02/16/2011 | EP2282777A1 Topical combinations comprising an antimycotic agent and an antiviral agent |
02/16/2011 | EP2282776A1 Apoptosis inducer |
02/16/2011 | EP2282756A1 Methods of diagnosing, preventing and treating bone mass diseases |
02/16/2011 | EP2282739A2 Sequential administration of chemotherapeutic agents for treatment of cancer |
02/16/2011 | EP2282734A2 Method for protecting humans against superficial vasodilator flush syndrome |
02/16/2011 | EP2282729A1 Methods and compositions for treating inflammation and inflammation-related pathologies |
02/16/2011 | EP2282724A2 Modified drugs for use in liposomal nanoparticles |
02/16/2011 | EP1773450B1 Therapeutically combinations |
02/16/2011 | EP1577388B1 Adiponectin promoter and use thereof |
02/16/2011 | EP1455794B1 ClC-2 CHANNEL OPENER FOR TREATING GASTRIC OR BOWEL ULCER |
02/16/2011 | EP1424080B1 Gnrh agonist combination drugs |
02/16/2011 | CN101977924A Novel c-21-keto lupane derivatives preparation and use thereof |
02/16/2011 | CN101977912A Mtor inhibitor salt forms |
02/16/2011 | CN101977628A Alpha 7 nicotinic agonists and antipsychotics |
02/16/2011 | CN101977604A Fluoroquinolone derivatives for ophthalmic applications |
02/16/2011 | CN101977594A Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients |
02/16/2011 | CN101972478A 抗体治疗 Antibody therapy |
02/16/2011 | CN101797385B Oral calcium pharmaceutical composition |
02/15/2011 | US7888473 Non-functional P2X7 receptor |
02/15/2011 | US7888460 a mutant gliadin protein with the mutation in the epitope 62PQPQLPY68, or a fragment of such mutant protein (non-glidin sequence), decreases the ability of the epitope to induce a Tcell or antibody response |
02/15/2011 | US7888393 Transdermal compositions |
02/15/2011 | US7888391 Method for reducing the severity of neurological disorders |
02/15/2011 | US7888389 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
02/15/2011 | US7888341 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide; antitumor; antiproliferative agent; synergistic therapy for resistant; Bcr/Abl, leukemia |
02/15/2011 | US7888327 Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
02/15/2011 | US7888291 Substrates and assays for β-secretase |
02/15/2011 | US7888092 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
02/15/2011 | US7887847 promotes visual health and reduces or reverses visual acuity loss by reduced Vitamin E with addition of taurine, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and zeaxanthin |
02/15/2011 | US7887833 Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting |
02/15/2011 | US7887831 comprising synthetic apatite and supplementary bioactive agent such as biocompatible polysaccharide and anti-resorptive agent added ab initio; for treating orthopedic, periodontal and craniofacial indications |
02/15/2011 | US7887819 Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen |
02/15/2011 | US7887807 Anti-IL-12 antibodies and compositions |
02/15/2011 | US7887804 Methods for treating disease-states associated with RG1 using immunoconjugates |
02/15/2011 | US7887799 Antibodies to fibroblast growth factor-like polypeptides |
02/15/2011 | US7887796 for a disorder of a subject's heart involving loss of cardiomyocytes by administering an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart; Vitamin D3 Up-Regulated Protein-1 |
02/15/2011 | US7887795 processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient; making an enhanced, autologous fat graft comprising supplementing a first portion of extracted adipose tissue with an additive and a disaggregated population of adipose-derived cells |
02/15/2011 | US7887794 Lactic acid bacteria and their use in the treatment of cancer |
02/15/2011 | US7887792 Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction |
02/15/2011 | US7887599 Glycolic acid-lactic acid copolymers as bulking agent; soft tissue augmentation |
02/15/2011 | CA2633072C Analgesic compounds and process of manufacture |
02/15/2011 | CA2529452C Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis |
02/15/2011 | CA2483594C Use of edg receptor binding agents in cancer |
02/15/2011 | CA2480562C 5-substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as ptpase 1b inhibitors |
02/15/2011 | CA2461348C [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain |
02/15/2011 | CA2460340C Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
02/15/2011 | CA2458856C Improved therapeutic protocols |
02/15/2011 | CA2452445C Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
02/15/2011 | CA2451483C Methods for detecting and monitoring cox-2 rna in plasma and serum |
02/15/2011 | CA2451043C Enhanced drug delivery in transdermal systems |
02/15/2011 | CA2446864C Inhibitors of src and other protein kinases |
02/15/2011 | CA2433535C Materials and methods relating to protein aggregation in neurodegenerative disease |